Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a

Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a

Oct 28, 2017
Source URL: https://qa1.novartis.us/news/media-releases/novartis-pivotal-data-show-children-and-adolescents-relapsing-ms-had-82-lower-relapse-rate-fingolimod-vs-interferon-beta-1a-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-pivotal-data-show-children-and-adolescents-relapsing-ms-had-82-lower-relapse-rate-fingolimod-vs-interferon-beta-1a-0